# A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

Source: https://onco.cc/trials/nct06637501/  
OnCo record `nct06637501` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sonrotoclax and Zanubrutinib in chronic lymphocytic leukaemia, run by BeOne Medicines, active and no longer recruiting.

## Summary

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia is a phase 2 interventional study registered as NCT06637501 by BeOne Medicines, with 94 participants enrolled, started 2024-11-14 and due to reach its primary completion in 2026-11. Interventions recorded: Sonrotoclax and Zanubrutinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06637501
- Phase: 2
- Setting: A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia
- Sponsor: BeOne Medicines
- Enrolled: 94

## Sources

- ClinicalTrials.gov NCT06637501: https://clinicaltrials.gov/study/NCT06637501

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Sonrotoclax](https://onco.cc/drugs/sonrotoclax/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct06637501.json